摘要
探讨拉米夫定耐药性乙型肝炎的治疗方法。将46例拉米夫定耐药性乙型肝炎随机分为A、B两组,均在继续服用拉米夫定的基础上对症保肝治疗,A组病例加用博尔泰力(400-600)mg/d,肌注;3个月为一个疗程,治疗结束观察比较两组患者ALT、HBVDNA、HBeAg的变化及综合疗效;A组患者ALT复常率、HBVDNA及HBeAg阴转率分别为64.0％(16/25)、56.0％(14/25)、42.8％(9/21),而B组分别为28.6％(6/21)、9.5％(2/21)、11.1％(2/18),两组比较差异有显著性(P<0.005或P<0.05);两组均无严重的不良反应及病情恶化。博尔泰力对拉米夫定耐药性乙型肝炎同样有效,可作为拉米夫定耐药性乙型肝炎治疗失败后的补救治疗。
To explore the ways in treating lamivudine resistant hepatitis B. 46 patients with chronic hepatitis B resistant to lamivu-dine were randomly allocated into two groups: group A and group B, and continued to study for three months. All patients in two groups received the basic treatment of lamivudine and 'protect liver' therapy. The patients in group A also received Proteli (400 - 600)mg/d, im. The changes of serum HBVDNA, HBeAg and alamine aminotransferase (ALT) in two groups were compared. The ALT normalization rate, HBVDNA and HBeAg sero- negative rate were 64.0% (16/25),56.0%(14/25)and 42.8%(9/ 21), higher than that of in group B which were 28.6% (6/21),9.5% (2/21) and 11.1% (2/18),respectively (P less than 0.005 or less than 0.05). There were no severe side - effects and depravation of the illness state. This study provides evidence that Proteli can be an eflective treatment for lamivudine - resistant hepatitis B.
出处
《临床肝胆病杂志》
CAS
北大核心
2003年第2期106-107,共2页
Journal of Clinical Hepatology
关键词
乙型肝炎
拉米夫定
博尔泰力
治疗作用
Lamivudine- resistant hepatitis B
Proteli
treating effect
